The immune checkpoint molecule programmed cell death 1 (PD-1) and its ligands PD-L1 and PD-L2 have been shown to play key roles in inhibiting T cell activity in the tumor microenvironment, not only in solid cancers but also in hematologic malignancies [10]. This evidence concerns the gene PDCD1LG2 and neoplasm.